Celgene ($CELG) snapped up Avila Therapeutics and its early-stage Btk inhibitor in a "grand slam" buyout that could hit $925 million with milestone payments. And not to be left out of the day's M&A fervor, Amgen ($AMGN) picked up Micromet ($MITI) for $1.2 billion, citing its "better way to kill tumor cells" as part of the attraction. Article | Report